Omlyclo® is a biosimilar brand of omalizumab which was listed on the Pharmaceutical Benefits Scheme (PBS) on 1 August 2025. Omlyclo® is listed under the Section 100 Highly Specialised Drugs Program (HSD Program).
About this resource
Publication date:
Publication type:
Fact sheet
Audience:
General public
Language:
English
Part of a collection: